Bone loss in SMART study
Mark Mascolini, for NATAP.org People randomised to continuous antiretroviral therapy in the SMART trial lost more bone mineral density (BMD) than those randomised to intermittent therapy, according to...
View ArticleHigh rate of rash in HIV-negative volunteers combining raltegravir and darunavir
Mark Mascolini, for NATAP.org Rash flared in 8 of 18 HIV-negative healthy adults (44%) combining raltegravir and darunavir/ritonavir in a pharmacokinetic (PK) study, and in one case the rash was...
View ArticleGenetic markers linked to early discontinuation of three antiretrovirals
Mark Mascolini, natap.org Pharmacogenetic markers that purportedly signal antiretroviral side effects predicted discontinuation of atazanavir, efavirenz, and tenofovir (but paradoxically not abacavir)...
View ArticleCD4 count >250 not predictive of rash-associated hepatoxicity among women...
Polly Clayden, HIV i-Base Nevirapine (NVP)-containing HAART is the most frequently used regimen in resource-limited countries. In 2004 Boehringer-Ingelheim, manufacturers of nevirapine (Viramune)...
View ArticleHDL particle concentration predicts cardiovascular disease in SMART
Nathan Geffen, TAC Daniel Duprez presented a nested case-control study from the SMART study showing that intermittent HAART was associated with a decrease in high-density lipoprotein (HDL) particle...
View ArticleIntensive smoking cessation programme reports limited success at 6 months
Simon Collins, HIV i-Base The scale of the problem of smoking, often highlighted in discussions of the abacavir data with a comment such as patients would reduce their risk more from stopping smoking...
View ArticleAssessing the cardiovascular impact of HIV, abacavir, and new signals for...
Nathan Geffen, TAC and Simon Collins, HIV i-Base Peter Reiss summarised the growing number of studies on the relationship between abacavir and cardiovascular disease (CVD). [1] Four of six studies show...
View ArticleTenofovir and renal safety
Simon Collins, HIV i-Base A couple of posters presented interesting data relating to renal safety associated with tenofovir. Firstly, and encouragingly, a sub-study from the international DART study...
View ArticleLipid and metabolic changes with ARV combinations
Simon Collins, HIV i-Base Lipid results can be complicated to interpret, especially between studies, given the lack of consistency in the method of reporting. Changes in lipid parameters, both from...
View ArticleRaltegravir body composition study: 48-week DEXA results
Simon Collins, HIV i-Base While some aspects of the lipodystrophy syndrome are better understood and managed, fat accumulation (lipohypertrophy), principally central visceral adipose tissue (VAT),...
View ArticleVisceral adipose tissue returns to baseline after stopping therapeutic...
Simon Collins, HIV i-Base Central fat accumulation remains one of the most distressing but least understood metabolic complications, with very limited management options. Several studies have reported...
View ArticleGender and race differences in lipodystrophy symptoms
Simon Collins, HIV i-Base The prevalence, type and severity of lipodystrophy in the Ontario Cohort Study was assessed using the ACTG body image questionnaire. Results from a cohort study of 746...
View ArticleHIV disease and renal function
Simon Collins, HIV i-Base Although earlier ARVs including AZT and indinavir were associated with renal toxicity, the focus on routine renal monitoring has increased significantly due to the widespread...
View ArticleGSK issues Dear Doctor letter in the US: fosamprenavir and cardiovascular risk
On 4 December 2009 GlaxoSmithKline (GSK) and FDA notified healthcare professionals and others of a potential association between fosamprenavir and myocardial infarction (heart attack) and dyslipidemia...
View Article11th International Workshop on Adverse Drug Reactions and Co-morbidities in...
Introduction We continue our reports from the 11th International Workshop on Adverse Drug Reactions ?and Co-morbidities in HIV?, held this year from 2628 October 2009 in Philadelphia, with this report...
View ArticleAlendronate improves bone mineral density in HIV-positive people with...
Simon Collins, HIV i-Base A small randomised placebo-controlled study (ANRS 120) showed that alendronate therapy (70mg once-weekly) significantly increased bone mineral density (BMD) at the...
View ArticleCentral fat accumulation remains a significant problem in patients starting...
Simon Collins, HIV i-Base A cross-sectional study from two large French hospitals presented at EACS was important for confirming that central fat accumulation (CFA), one of the symptoms associated with...
View ArticleVitamin D deficiencies in HIV management
Nathan Geffen, TAC HTB has run several articles on vitamin D deficiencies in previous issues in relation to bone problems, tenofovir and efavirenz. There is increasing concern and research about...
View ArticleHIV-positive people in the HOPS cohort have 4-fold risk of fracture compared...
Simon Collins, HIV i-Base Over the last ten years HTB has reported numerous studies of lower bone mineral density and higher rates of osteopenia and osteoporosis in HIV-positive people compared to...
View ArticleACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naive patients
?Simon Collins, HIV i-Base The few randomised clinical trials using currently licensed antiretrovirals worth highlighting from CROI partly stood out because there were fewer comparative studies that at...
View Article
